Even as the pace of vaccination against covid-19 has steadily accelerated — hitting an average of 1.3 million doses a day in the last days of January — the frustration felt by many of those unable to secure an appointment hasn’t waned.
More
April 30 will mark the end of the first 100 days of President Joe Biden’s tenure. That’s a benchmark presidents often set for making good on high-priority campaign promises.
More
Vaccinations against the coronavirus are off to a slow and chaotic start in the United States, but the country’s top infectious disease expert held out hope Sunday that the pace will soon pick up.
More
Reports about the release of COVID-19 vaccines by the end of the year are promising, but plans for distribution are still being worked out.
More
COVAX now has agreements in place to access nearly two billion doses of several promising vaccine candidates, and laid the groundwork for further doses to be secured through contributions from donors
More
The Food and Drug Administration recently granted emergency use authorization to a coronavirus vaccine from Pfizer, and approval for Moderna’s version is anticipated shortly.
More
As U.S. hospitals ramped up COVID-19 vaccinations Tuesday with the first vaccine approved for emergency use, federal regulators issued a favorable review of a second vaccine needed to combat the country's worsening crisis.
More
today announced a partnership with Moderna Inc. to utilise the Elecsys® Anti-SARS-CoV-2 S antibody test in Moderna's mRNA-1273 vaccine research trials. This will facilitate the quantitative measurement of SARS-CoV-2 antibodies and help to establish a correlation between vaccine-induced protection and levels of anti-receptor binding domain (RBD) antibodies.
More
Primary efficacy analysis of the Phase 3 COVE study of mRNA-1273 involving 30,000 participants included 196 cases of COVID-19, of which 30 cases were severe
More